Open Label, Uncontrolled, Pilot, Phase II Study of Histone-Deacetylase Inhibitor ITF2357 Administered Orally to Subjects With Chronic Lymphocytic Leukemia (CLL) Refractory/Relapsed After Conventional Chemotherapy or Relapsed After Autologous Bone Marrow Transplantation.

Trial Profile

Open Label, Uncontrolled, Pilot, Phase II Study of Histone-Deacetylase Inhibitor ITF2357 Administered Orally to Subjects With Chronic Lymphocytic Leukemia (CLL) Refractory/Relapsed After Conventional Chemotherapy or Relapsed After Autologous Bone Marrow Transplantation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 May 2013

At a glance

  • Drugs Givinostat (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2012 Planned end date changed from 1 Jul 2010 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Actual patient number (1) added as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Planned End Date changed from 1 Apr 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top